Compare FUBO & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUBO | AKBA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.2M | 729.1M |
| IPO Year | 2020 | 2014 |
| Metric | FUBO | AKBA |
|---|---|---|
| Price | $1.34 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $3.98 | ★ $5.92 |
| AVG Volume (30 Days) | ★ 19.1M | 3.5M |
| Earning Date | 02-03-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,855,678,000.00 | $225,071,000.00 |
| Revenue This Year | $10.74 | $52.41 |
| Revenue Next Year | $10.03 | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.60 | ★ 32.49 |
| 52 Week Low | $1.31 | $1.20 |
| 52 Week High | $4.72 | $4.08 |
| Indicator | FUBO | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 15.09 | 34.58 |
| Support Level | $1.31 | $1.33 |
| Resistance Level | $1.61 | $1.60 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 3.54 | 12.22 |
FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.